Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bolstering its growing portfolio of fibrosis treatments, Bristol-Myers Squibb has paid $100 million upfront for access to Nitto Denko’s siRNA molecules targeting heat shock protein 47. Nitto Denko’s lead HSP47 inhibitor, which blocks a protein responsible for regulating collagen synthesis and deposition, is in Phase Ib studies to treat advanced liver fibrosis caused by nonalcoholic steatohepatitis. BMS has in recent years assembled a pipeline of fibrosis assets through deals that include options to buy Galecto Biotech and Promedior.
This article has been sent to the following recipient: